A 12-week, double-blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment.
« Long term observational, prospective study to collect in a real-life setting data on the retention, effectiveness, safety, treatment pattern, quality of life (QoL), and efficiency of secukinumab in adult patients with moderate to severe plaque psoriasis. ».
A phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of INCB054828 in subjects with advabced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 translocations who failed previous therapy
Mepolizumab long-term access programme for subjects who participated in study MEA115921 (placebo-controlled study of Mepolizumab in the treatment of Eosinophilic Granulomatosis with Polyangiitis in subjects receiving standard-of-care therapy.»
Evolution de la dimension psychopathique chez des patients souffrants de troubles mentaux dans une population de patients hospitalisés sous contrainte dans une unité de mise en observation dans un hôpital général
A prospective multi-centre, randomised, controlled study to evaluate the safety and preliminary effectiveness of NVD-001 for the treatment of low grade degenerative lumbar spondylolisthesis by interbody fusion (L1 – S1). (The NVD-001 Spine1 Study)
Recherche de corrélations pronostiques, clinico-radiologiques, pathologiques et moléculaires avec les différences de métabolisme au PET-CT à la 11C-méthionine au sein des oligodendrogliomes de grade II
A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of multiple VAY736 doses administered subcutaneously in patients with moderate to severe Sjögren's syndrome
A randomized, double-blind, placebo-controlled, multicenter, phase 2 study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active psoriatic arthritis
MAXIMISE (managing axial manifestations in psorIatic arthritis with secukinumab), a randomized, double-blind, placebo-controlled, multicenter, 52-week study to assess the efficacy and safety of secukinumab 150 mg or 300 mg s.c. in patients with active psoriatic arthritis and axial skeleton involvement who have inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs)
A prospective, non-interventional study to evaluate the clinical effectiveness, the consistency of evaluation scores, the quality of life, safety and tolerability of tocilizumab subcutaneous in patients with rheumatoid arthritis in daily clinical practice